Oncotype DX prostate cancer assay diagnostic data

Genomic Health and researchers at the University of California, San Francisco, reported top-line data from a clinical validation study in patients with early stage prostate cancer showing that the Oncotype DX Genomic Prostate Score (GPS) met the primary endpoint by prospectively predicting adverse pathology from prostate needle biopsy tumor tissue samples. The company declined to disclose detailed data from the study. Final data will be submitted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando in February. ...